Solvias will provide analytical release testing services for the first genome-edited cell therapy, CASGEVY™, to treat sickle cell disease in patients aged 12 and older. The therapy has gained FDA approval and conditional approval from the EMA for severe sickle cell disease and transfusion-dependent beta thalassemia treatments.

‘Cyber incident’ continues to disrupt computer networks at some Sudbury-area schools – CTV News
Several schools in the Sudbury area continue to face disruptions in their computer networks due to an ongoing cyber incident. This has caused challenges for